These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33991015)

  • 1. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.
    Hong S; Dobricic V; Ohlei O; Bos I; Vos SJB; Prokopenko D; Tijms BM; Andreasson U; Blennow K; Vandenberghe R; Gabel S; Scheltens P; Teunissen CE; Engelborghs S; Frisoni G; Blin O; Richardson JC; Bordet R; ; Lleó A; Alcolea D; Popp J; Clark C; Peyratout G; Martinez-Lage P; Tainta M; Dobson RJB; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Tanzi RE; Ten Kate M; Wittig M; Franke A; Lill CM; Barkhof F; Lovestone S; Streffer J; Zetterberg H; Visser PJ; Bertram L
    Alzheimers Dement; 2021 Oct; 17(10):1628-1640. PubMed ID: 33991015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.
    Neumann A; Ohlei O; Küçükali F; Bos IJ; Timsina J; Vos S; Prokopenko D; Tijms BM; Andreasson U; Blennow K; Vandenberghe R; Scheltens P; Teunissen CE; Engelborghs S; Frisoni GB; Blin O; Richardson JC; Bordet R; Lleó A; Alcolea D; Popp J; Marsh TW; Gorijala P; Clark C; Peyratout G; Martinez-Lage P; Tainta M; Dobson RJB; Legido-Quigley C; Van Broeckhoven C; Tanzi RE; Ten Kate M; Lill CM; Barkhof F; Cruchaga C; Lovestone S; Streffer J; Zetterberg H; Visser PJ; Sleegers K; Bertram L;
    Genome Med; 2023 Oct; 15(1):79. PubMed ID: 37794492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
    Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
    Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study.
    Thordardottir S; Almkvist O; Johansson C; Zetterberg H; Blennow K; Graff C
    J Alzheimers Dis; 2020; 76(3):941-953. PubMed ID: 32568193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
    BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
    Antonell A; Tort-Merino A; Ríos J; Balasa M; Borrego-Écija S; Auge JM; Muñoz-García C; Bosch B; Falgàs N; Rami L; Ramos-Campoy O; Blennow K; Zetterberg H; Molinuevo JL; Lladó A; Sánchez-Valle R
    Alzheimers Dement; 2020 Feb; 16(2):262-272. PubMed ID: 31668967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
    Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.
    Schindler SE; Li Y; Todd KW; Herries EM; Henson RL; Gray JD; Wang G; Graham DL; Shaw LM; Trojanowski JQ; Hassenstab JJ; Benzinger TLS; Cruchaga C; Jucker M; Levin J; Chhatwal JP; Noble JM; Ringman JM; Graff-Radford NR; Holtzman DM; Ladenson JH; Morris JC; Bateman RJ; Xiong C; Fagan AM;
    Alzheimers Dement; 2019 May; 15(5):655-665. PubMed ID: 30846386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.
    Mielke MM; Przybelski SA; Lesnick TG; Kern S; Zetterberg H; Blennow K; Knopman DS; Graff-Radford J; Petersen RC; Jack CR; Vemuri P
    Alzheimers Dement; 2021 May; 17(5):801-812. PubMed ID: 33663022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
    Bos I; Vos S; Vandenberghe R; Scheltens P; Engelborghs S; Frisoni G; Molinuevo JL; Wallin A; Lleó A; Popp J; Martinez-Lage P; Baird A; Dobson R; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Bertram L; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Visser PJ
    Alzheimers Res Ther; 2018 Jul; 10(1):64. PubMed ID: 29980228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
    Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset.
    Hong S; Prokopenko D; Dobricic V; Kilpert F; Bos I; Vos SJB; Tijms BM; Andreasson U; Blennow K; Vandenberghe R; Cleynen I; Gabel S; Schaeverbeke J; Scheltens P; Teunissen CE; Niemantsverdriet E; Engelborghs S; Frisoni G; Blin O; Richardson JC; Bordet R; Molinuevo JL; Rami L; ; Kettunen P; Wallin A; Lleó A; Sala I; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Dobson RJB; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Wittig M; Franke A; Tanzi RE; Visser PJ; Bertram L
    Transl Psychiatry; 2020 Nov; 10(1):403. PubMed ID: 33223526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.
    Falgàs N; Ruiz-Peris M; Pérez-Millan A; Sala-Llonch R; Antonell A; Balasa M; Borrego-Écija S; Ramos-Campoy O; Augé JM; Castellví M; Tort-Merino A; Olives J; Fernández-Villullas G; Blennow K; Zetterberg H; Bargalló N; Lladó A; Sánchez-Valle R
    Hum Brain Mapp; 2020 Jun; 41(8):2004-2013. PubMed ID: 31944489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults.
    Racine AM; Merluzzi AP; Adluru N; Norton D; Koscik RL; Clark LR; Berman SE; Nicholas CR; Asthana S; Alexander AL; Blennow K; Zetterberg H; Kim WH; Singh V; Carlsson CM; Bendlin BB; Johnson SC
    Brain Imaging Behav; 2019 Feb; 13(1):41-52. PubMed ID: 28600739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
    Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
    EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds.
    Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A
    J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.